Spero Therapeutics, Inc. announced that Satyavrat “Sath” Shukla, Spero’s current Chief Financial Officer and Treasurer, will serve as Spero’s President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023. Mr. Shukla will succeed Spero’s current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023. The current Chairman of the Board, Milind Deshpande, Ph.D., will remain on the Board as an independent director, and current Board member, Patrick Vink, MD., will be appointed Lead Independent Director.

Mr. Shukla brings more than two decades of strategic and financial leadership experience to the role of CEO, including the last three years as Spero’s CFO and Treasurer. During his tenure at Spero, he has led all aspects of the Company’s finance, accounting, and business development functions, and has played an instrumental role in securing strategic investments and licensing agreements from GSK and Pfizer Inc. Spero has launched a search for the next CFO to succeed Mr. Shukla. Until this search is completed, the Board has appointed Stephen J. DiPalma as Interim CFO and Treasurer, effective August 1, 2023.